-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 VcFTKf2hHfAwH8AjKwqv0mfpFgkRKATW01ii335Xz1wNqSQdCsFYkuzTzyF4ZF0k
 hd9Kh+cDEZsZsjKlqXevkg==

<SEC-DOCUMENT>0000950117-03-002665.txt : 20030620
<SEC-HEADER>0000950117-03-002665.hdr.sgml : 20030620
<ACCEPTANCE-DATETIME>20030620155248
ACCESSION NUMBER:		0000950117-03-002665
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20030619
FILED AS OF DATE:		20030620

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			BIO PARTNERS LP
		CENTRAL INDEX KEY:			0001240418
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19879
		FILM NUMBER:		03751901

	BUSINESS ADDRESS:	
		STREET 1:		1 MEADOW DRIVE
		CITY:			LAWRENCE
		STATE:			NY
		ZIP:			11559
		BUSINESS PHONE:		516 295 1762

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOSPECIFICS TECHNOLOGIES CORP
		CENTRAL INDEX KEY:			0000875622
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				113054851
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		35 WILBUR ST
		CITY:			LYNBROOK
		STATE:			NY
		ZIP:			11563
		BUSINESS PHONE:		5165937000

	MAIL ADDRESS:	
		STREET 1:		35 WILBUR STREET
		CITY:			LYNBROOK
		STATE:			NY
		ZIP:			11563
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>a35614.xml
<DESCRIPTION>BIO PARTNERS LP
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>
    <schemaVersion>X0101</schemaVersion>

    <documentType>3</documentType>
<periodOfReport>2003-06-19</periodOfReport>
    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0000875622</issuerCik>
        <issuerName>BIOSPECIFICS TECHNOLOGIES CORP</issuerName>
        <issuerTradingSymbol>BSTCE</issuerTradingSymbol>
</issuer>
<reportingOwner>
<reportingOwnerId>
            <rptOwnerCik>0001240418</rptOwnerCik>
            <rptOwnerName>BIO PARTNERS LP</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>  </rptOwnerStreet1>
            <rptOwnerStreet2>  </rptOwnerStreet2>
            <rptOwnerCity>  </rptOwnerCity>
            <rptOwnerState>  </rptOwnerState>
            <rptOwnerZipCode>  </rptOwnerZipCode>
        </reportingOwnerAddress>
            <reportingOwnerRelationship>
<isDirector>0</isDirector>
<isOfficer>0</isOfficer>
<isTenPercentOwner>1</isTenPercentOwner>
<isOther>0</isOther>
</reportingOwnerRelationship>
</reportingOwner>
<nonDerivativeSecurity>
<securityTitle>
<value>Common Stock</value>
</securityTitle>
<transactionAmounts>
<transactionShares>
<value>295312</value>
</transactionShares>
</transactionAmounts>
<ownershipNature>
<directOrIndirectOwnership>
<value>D</value>
</directOrIndirectOwnership>
</ownershipNature>
</nonDerivativeSecurity>
<derivativeSecurity>
<securityTitle>
<value>12% Senior Secured Convertible Note</value>
</securityTitle>
<conversionOrExercisePrice>
<value>2.50</value>
<footnoteId id="F1"/>
</conversionOrExercisePrice>
<exerciseDate>
<value>2003-06-19</value>
</exerciseDate>
<expirationDate>
<value>2005-06-19</value>
</expirationDate>
<underlyingSecurity>
<underlyingSecurityTitle>
<value>Common Stock</value>
</underlyingSecurityTitle>
<underlyingSecurityShares>
<value>456750</value>
<footnoteId id="F1"/>
</underlyingSecurityShares>
</underlyingSecurity>
<ownershipNature>
<directOrIndirectOwnership>
<value>D</value>
</directOrIndirectOwnership>
</ownershipNature>
</derivativeSecurity>
<footnotes>
<footnote id="F1">Reporting Person may exercise, at a conversion price
(subject to various typical adjustments) of $2.50 per share of Common Stock of Biospecifics Technologies Corp., up to $1,141,875 of the aggregate principal amount of the Convertible Note. If the Reporting Person fully exercised such conversion rights, the Reporting Person would recieve 456,750 shares of the Common Stock of Biospecifics Technologies Corp.</footnote>
</footnotes>
<ownerSignature>
<signatureName>/s/ Jeffrey K. Vogel, in his capacity as President of Bio Management, Inc., the sole general partner of the Reporting Person</signatureName>
<signatureDate>2003-06-19</signatureDate>
</ownerSignature>
</ownershipDocument>

</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----